Edesa Biotech is trading at $5.53, up +5.59% on August 11, 2026, as investors respond positively to immunology-sector deal activity.
- argenx agreed to acquire Forte Biosciences for approximately $2.2 billion in cash, including a $77-per-share tender offer.
- No new company-specific Edesa announcement was identified.